Filing Flows › Novartis AG (NVS) › Free cash flow
Novartis AG (NVS) free cash flow by quarter
Novartis AG's free cash flow was $5.1B in Q3 2026 (third quarter 2026), -8% from Q2 2026. Over the last 6 quarters it ranged from $1.7B (Q4 2025) to $6.3B (Q2 2025).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $5.1B | -8% | -18% |
| Q2 2026 | $5.6B | +67% | -12% |
| Q1 2026 | $3.3B | +101% | — |
| Q4 2025 | $1.7B | -73% | — |
| Q3 2025 | $6.2B | -2% | — |
| Q2 2025 | $6.3B | — | — |
Q3 2026 at a glance
Novartis AG, Q3 2026: revenue $14.5B (+4% year over year), operating margin 12.7%, net earnings $1.2B, operating cash flow $5.5B. The chart follows the revenue to costs, profit and cash.
Questions
What is Novartis AG's free cash flow?
Novartis AG's free cash flow was $5.1B in Q3 2026 (third quarter 2026), -8% from Q2 2026.
How has Novartis AG's free cash flow changed?
Over the last 6 quarters it ranged from $1.7B (Q4 2025) to $6.3B (Q2 2025).